Release Archive2021-01-12T09:21:10+01:00


1803, 2021

Kommuniké från årsstämma

Pressmeddelande: Årsstämma i Lipum AB (publ), 556813-5999 (”Bolaget”) hölls den 17 mars 2021 i Umeå. Genom förhandspoströstning varvid aktieägarna, i enlighet med kallelsens förslag, i huvudsak fattade följande beslut. [...]

403, 2021

Kallelse till årsstämma

Pressmeddelande: Umeå, 4 Mars 2021. Kallelse till Kallelse till årsstämma i Lipum AB. Aktieägarna i Lipum AB, 556813-5999, kallas härmed till årsstämma den 17 mars 2021. Som en försiktighetsåtgärd [...]

2302, 2021

Biologics are a success factor according to Lipum

News: Umeå, 23 February 2021. Article in Biostock Lipum develops a new biological drug for chronic inflammatory diseases. According to one study, the probability for approval of biological drugs is [...]

2801, 2021

Lipum planerar notering vid Nasdaq First North

Pressmeddelande: Umeå, 28 januari, 2021. Lipum AB med säte i Umeå grundades år 2010. Nu förbereds kapitalanskaffning genom en notering förutsatt godkänd ansökan vid Nasdaq First North Growth Market under [...]

2601, 2021

Marina Norberg new CFO at Lipum

Press release: Umeå, January 26, 2020. Lipum AB has appointed Marina Norberg Chief Financial Officer (CFO). Marina Norberg has extensive experience as an approved auditor at PwC and as authorized [...]

1901, 2021

Lipum to carry out an IPO during 2021

News: Umeå, 19 January 2021. Article in Biostock Currently Lipum is planning an IPO (Initial Public Offering) to finance the start of the clinical trials required to take SOL-116 all [...]

312, 2020


In the magazine "Skelett och ledhälsa” our founders Professor Olle Hernell, Dr. Susanne Lindquist and Professor Lennart Lundberg were interviewed about our drug candidate SOL-116. SOL-116 is the antibody that [...]

2311, 2020


At Biostock Life Science Summit last week our CEO Einar Pontén presented the recent progress in bringing our lead candidate SOL-116 towards clinical verification. He also briefly [...]

1311, 2020

Digital Resi – Three day conference

Lipum will participate at Digital RESI (Redefining Early Stage Investments), a dedicated global partnering event. The challenge for the attendees will be the geographic time zone issues and that may [...]

1011, 2020

Biostock Life Science Summit

Our CEO Einar Pontén is preparing for BioStock Life Science Summit on 17 November at 12:30. He will present our unique approach to treat chronic inflammations and the progress with [...]

610, 2020

Norrlandsfonden invests in lipum

Susanne Lindquist and Olle Hernell, two of Lipums founders. - Lipum is a very exciting company in drug development that also has a strong sustainability perspective, says Anna Hedström, Norrlandsfonden, [...]

2909, 2020

Next wave in Immune Therapeutics

On 29-30 September 2020, our CEO Einar Pontén together with Professor Olle Hernell will attend the virtual event by Johnson & Johnson Innovation, in collaboration with Janssen Immunology. Johnson & [...]

1709, 2020

Research engineer is strengthen our team

- It´s going to be both fun and exciting to contribute to Lipum's progress, says Assar Bäckman, research engineer. Assar comes with extensive experience in the field of gene expression [...]

1808, 2020

Shareholders meeting in Lipum

News: Umeå, 18 August 2020. Lipum invites to a meeting with the shareholders On August 27, Lipum shareholders will meet virtually. The recent progress and plans for the future will [...]

1408, 2020


Pressmeddelande: Umeå, 17 August 2020. Kallelse till extra bolagsstämma Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till extra bolagsstämma fredagen den 28 augusti 2020, kl. 12:00 på [...]

1308, 2020

Lipum prepares for LSX Nordic Virtual event

News: Umeå, 13 August 2020. Lipum participate in LSX Nordic Viritual event 1-4 September. LSX is a community of senior life science decision makers where they connect senior life science [...]

2707, 2020

Growing up with Juvenile Idiopathic Arthritis

Clara Laurell. Foto: Roger Larsson, Hallandsposten News: Umeå, 27 August 2020. Growing up with Juvenile Idiopathic Arthritis Every year, more than 200 Swedish children are diagnosed with Juvenile Idiopathic Arthritis [...]

1106, 2020

Lipum kallar till årsstämma

Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till årsstämma torsdagen den 25 juni 2020, kl. 16:00 på Tvistevägen 48C i Umeå. Aktieägare som önskar delta i stämman [...]

1205, 2020

Another step towards a novel treatment

What effect has elevated levels of our target molecule on human blood? Together with our partner Immuneed we will increase our understanding. Another step towards a novel treatment of inflammatory diseases.

505, 2020

The production development at Abzena proceeds successfully

At last our fully humanised antibody and lead candidate SOL-116 will be traveling soon. The production development at Abzena proceeds successfully and according to plan. Downstream processing and quality control have [...]

1604, 2020

Lipum strengthens Board with experienced docent

At the end of last year, we were able to announce that the cell line had been completed. Recently, another good news was brought, a significant reinforcement to the company's [...]

1603, 2020

SwedenBIO opens a Q&A function

SwedenBIO has opened up a Q&A function on their website. Here, questions can be asked about the Swedish life science industry's role in meeting current challenges. Click here to get to [...]

503, 2020

Dr Kristian Sandberg new board member of Lipum

Dr Kristian Sandberg is an associate professor in immunology and an experienced leader in the pharmaceutical industry’s research and development. Sandberg has over 20 years’ experience from AstraZeneca in various [...]

2502, 2020

Lipum will attend Bio-Europe Spring 2020

In March Lipum will attend Bio-Europe Spring, Europe's largest partnership conference for the biotechnology industry. Meet us there! Visit site:

1702, 2020

Lipum kallar till extra bolagsstämma

Aktieägarna i Lipum AB, org. nr. 556813-5999, kallas härmed till extra bolagsstämma tisdagen den 3 mars 2020, kl. 13:00 på Tvistevägen 48C i Umeå. Styrelsen föreslår att Dr Kristian Sandberg [...]

1812, 2019

A milestone has been reached

After an intensive and targeted work, the cell line development of our lead drug candidate SOL-116 has been finalized. Now the production optimization and scale up has been initiated and [...]

2611, 2019

Pharma Outsourcing 2019

“How we selected our CMO partner for cell line and production development of Lipum´s lead candidate drug SOL-116” […]

511, 2019

Lipum in preparation for Bio-Europe

– Our goal is to meet with investors interested in our next financing round,  says our CEO Einar Ponten in preparation for Bio-Europe in Hamburg, 11-13 November. […]

1510, 2019

BioStock Life Science Summit

Life Science industry leaders, financing experts and qualified investors gather in Lund. Welcome to meet us at Biostock Life Science Summit, october 23th-24th. […]

1909, 2019

Lipum to Basel for one-to-one meetings

- We are looking forward to one-to-one meetings in Basel, among the largest biopharma hubs in Europe, says CEO Einar Pontén when Lipum is preparing to participate at the 19th [...]

2108, 2019

Lipum presents at Biostock Live

On August 27, Lipums CEO Einar Pontén will present our recent progress towards a novel treatment of chronic inflammatory diseases. The presentation will be broadcasted live on the web from [...]

1408, 2019

Lipum invites to shareholders meeting

On August 28, Lipum shareholders will meet at Clarion Hotel Arlanda Airport. The recent progress and plans for the future will be presented and discussed. More detailed information will be [...]

107, 2019

A valuable and engaged support

We are grateful for the valuable and engaged support from our Umeå Biotech Incubator coach Anne-Charlotte Aronsson. After three years with us she is now moving on and we hope [...]

1406, 2019

Kallelse till årsstämma i Lipum AB

Aktieägarna i Lipum AB, org. nr. 556813-5999 (“Lipum”), kallas härmed till årsstämma fredagen den 28 juni 2019, kl. 09:00 på Tvistevägen 48C i Umeå. […]

1705, 2019

Getting roasted by investors

As a Horizon 2020 beneficiary we are invited to the SME Instrument Phase 2 Welcome Day organized by the European Innovation Council (EIC) Pilot in Brussels, May 22-23. Besides business [...]

805, 2019

Welcome to Lipum, Pernilla!

Name: Pernilla Abrahamsson Education: PhD in medicine Age: 46 Family: Married, two teenagers Hobbies: We spend a lot of time in the cottage and the whole family goes [...]

1903, 2019

Lipum and Abzena sign integrated CMC agreement

Press release march 19 2019 Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a [...]

603, 2019

Umeåföretag tar nästa steg mot ett nytt läkemedel

Pressrelease 3 juni, 2019 Ladda ned pressrelase: Investerare satsar 25 MSEK på nytt läkemedel (pdf) » Umeåföretaget Lipum utvecklar ett biologiskt läkemedel för behandling av kroniska inflammationer. Tidigare pre-kliniska studier [...]

403, 2019

Lipum to NASDAQ

On 6-7 March, Lipum attends a pitching event for Deep Tech companies in Stockholm hosted by The European Innovation Council (EIC) pilot and Nasdaq. The event is exclusively organised for [...]

502, 2019

Exclusive partnering with nordic life science startups

Thursday 7th February we will spend with potential investors and partners together with 14 participating companies from Umeå. It's the annual Biotech Umeå Investment Day 2019. We are looking forward [...]

1701, 2019

Lipum makes a share issue for faster progress

Being a European Commission Horizon 2020 beneficiary has a distinct positive impact on our development. The 2.2 M€ grant enables us to proceed faster towards a new drug against chronic [...]

2211, 2018

Biotech Umeå Investment Day 2019

An opportunity for investors on Thursday the 7th of February 2019. An efficient full day of exclusive one-to-one partnering at the Biotech Umeå Investment Day 2019. Book your meeting with [...]

3009, 2018

BIO-Europe in Copenhagen, Nov 5-7 2018

Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén and our CMC Project Manager Mats Reslow at BIO-Europe 2018 in Copenhagen, Nov 5-7. [...]

2908, 2018

Lipum receives 2.2 M€ grant from Horizon 2020

Press release Aug 29, 2018 Lipum's unique approach for treatment of chronic inflammatory diseases receives 2.2 M€ support from EU Horizon 2020, the EU framework program for research and development, [...]

1508, 2018

Lipum company presentation at Biostock live

Lipum and some listed nordic life science companies will make company presentations in Stockholm at Nyhetsbyrån Direkt on August 29, 2018. The event is organised by Biostock and will also [...]

2007, 2018

Lipum selected as finalist at NLSDays

An international panel of life science investors have selected Lipum as one of 12 companies for the final of the live pitch competition at the Nordic Life Science Days 2018. [...]

1506, 2018

Lipum received grant from SWElife

Our project "Validation of a biological candidate drug" has been granted support from SWElife "Projects for better health" program. The competition was fierce so the green tie was used during [...]

2603, 2018

Meet Lipum at Biotrinity in London, April 23-25

Learn more about our novel target for treatment of chronic inflammatory diseases at Biotrinity - A Leading Biopartnering and Investment Conference in London, April 23-25, 2018 We will tell you [...]

2401, 2018

Invest in Life Science at Grand Hôtel

Biotech Umeå Investment Day 2018 on February 1 at Grand Hôtel in Stockholm is a partnering event, for startups, investors and industrial partners within life science. Beside Lipum you can also [...]

1501, 2018

Lipum in EMBL Alumni Report 2017

The European Molecular Biology Laboratory (EMBL) was founded more than 40 years ago to be a centre of excellence for Europe’s most talented young scientists in the life sciences. In the Alumni Impact [...]

3011, 2017

Horizon 2020 – Seal of Excellence

Seal of Excellence Certificate by European Commission In response to Lipums application ”Novel Target for Treatment of Chronic Inflammatory Diseases” for SME Instrument 2 funding by EU’s Horizon 2020 an international [...]

211, 2017

November, meet us in Berlin and New York

Learn more about our novel target for treatment of chronic inflammatory diseases. We will attend: BIO-Europe in Berlin, Nov 6-8 Nordic-American conference in New York, Nov 13-14 RESI meeting in [...]

211, 2017

BIO-Europe in Berlin Nov 6-8, meet Lipum there.

Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén at BIO-Europe 2017 in Berlin, Nov 6-8. We will tell you more on our [...]

2509, 2017

17th Annual Biotech in Europe Forum

We invite investors to join us in the development towards better treatment of chronic inflammations. Meet us and learn more at the 17th Annual Biotech in Europe Forum, Basel, Sept [...]

1808, 2017

Meet Lipum at NLSDays in Malmö, Sept 12-14

Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at [...]

2806, 2017

Future medicine for treatment of chronic inflammation

Rheumatism is an autoimmune disease that causes chronic inflammation and pain. The inflammation can break down cartilage, adjacent bones, tendons and arteries. Also eyes and other organs can be affected. About [...]

2505, 2017

Lipum patent granted in Canada

Lipum AB is the assignee of a strong patent portfolio and the rights of the patent from the inventors and the results within the BSSL research have all been transferred [...]

1605, 2017

Lipum presenting at Anglonordic, London, May 31

We will present our recent advancements in the development of a biological drug for treatment of chronic inflammatory diseases. Pre-clinical results based on well established models have shown the importance [...]

1303, 2017

Meet Lipum at Bio-Europe Spring 2017

Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén or Chairman [...]

3012, 2016

Meet Lipum at Swiss Nordic Bio meeting in Zürich

Lipum is actively seeking partners and investors for a faster development of a new biological drug towards an unique target for treatment of autoimmune inflammatory diseases. Swiss Nordic Bio in [...]

2912, 2016

Dr Einar Pontén the new CEO at Lipum AB

Press release Dec 29, 2016 The Board of Directors of Lipum AB in Umeå has appointed Dr Einar Pontén new CEO. "We are very pleased to recruit an experienced force [...]



Go to Top